Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
Arslan
O
O
Akan
H
H
Koç
H
H
Beksaç
M
M
Ilhan
O
O
Ozcan
M
M
Yalçín
S
S
Gürman
G
G
Konuk
N
N
Uysal
A
A
D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000009:adverse effects*; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000009:adverse effects*; D004802:Eosinophilia / Q000453:epidemiology / Q000209:etiology*; D006086:Graft vs Host Disease / Q000097:blood* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D015994:Incidence; D007938:Leukemia / Q000150:complications / Q000628:therapy; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan; D008775:Methylprednisolone